Approved Study Database
| Ref. No. | Scientific Title | Principal investigator |
|---|---|---|
| 2022.371 | Multicentre assessment of liver frailty using the Liver frailty index in patients with unresectable hepatocellular carcinoma (HCC) undergoing transarterial chemoembolisation (TACE) or systemic therapy | Dr. LUI Rashid N.S. |
| 2025.878 | Cross Sectional Study on the Prevalence of Pituitary Adenomas in Lynch Syndrome | Dr. Lui Rashid N.S. |
| 2025.301 | Multicentre retrospective comparative study of early-onset colorectal cancer (EOCRC): Analysis of clinicopathological, familial and prognostic differences according to the geographical location | Dr. LUI Rashid N.S. |
| 2025.312 | The impact of contemporary neoadjuvant and adjuvant chemotherapy treatment regimens on recurrence and survival in resectable, borderline resectable, locally advanced and metastatic adenocarcinoma arising from IPMN and internal validation of 2023 KYOTO Guidelines: ADENO-IPMN 2 study | Dr. LUI Rashid N.S. |
| 2021.033 | Randomized Controlled Trial of Aspirin for the Prevention of Recurrence in Liver Cancer |
Dr. LUI Rashid Nok Shun 雷諾信 |
| 2022.323 | Effectiveness of the Current Use of Hospital Authority (HA) Mobile Application HA Go in Exercise Program for Knee Osteoarthritis (OA) in Local Elderly Patients |
Ms. LUI Sweetie R. 雷蕢珊 |
| 2009.282 | Socio-demographic Risk Factors for adolescent Sports Injury in Hong Kong: A Pilot Study | Ms. Lui Tai Wah |
| 2025.139 | Epidemiology of fusariosis in NTEC | Dr. LUI Tin Long |
| 2011.282 | EFFECTIVENESS OF TOE SPREADER & DYNAMIC HALLUX VALGUS STRAP ON FOOT FUNCTION FOR JUVENILE HALLUX VALGUS - PROSPECTIVE, CROSSOVER RANDOMIZED CONTROL TRIAL | Dr. Lui Tun Hing |
| 2009.369 | Determinants and barriers for help seeking in persons with self-harm and aggressive ideations | Dr. Lui Victor Wing Cheong |
| 2010.081 | Oncogenic Regulation of TIGAR by STAT3: A Mechanistic Study | Ph.D. LUI Vivian Wai Yan |
| 2017.145 | RAC1 Genomic Alterations Drive Head and Neck Cancer Progression |
Dr. LUI Vivian Wai Yan 呂偉欣 |
| 2017.293 | ALK/PIK3CA Genetic Coupling: Implications for Progression and Personalized Therapy in Head and Neck Cancer |
Dr. LUI Vivian Wai Yan 呂偉欣 |
| 2011.612 | Comparison of satisfaction with communication during general outpatient consultation of doctors and patients | Ms Lui Wai Yan |
| 2008.195 | High-Content Screening (HCS) Platform for Molecular Drug Testing, Therapeutic Target Identification and Mechanistic Signaling Studies in Asian Prevalent Cancers | Ph.D., Assistant Professor LUI Wai Yan Vivian |
| 2008.196 | Biological Implication of Elefated Serum Hepatocyte Growth Factor (HGF) in the Progressionof Nasopharyngeal Carcinoma (NPC) | Ph.D., Assistant Professor LUI Wai Yan Vivian |
| 2008.022 | Oncogenic Dependency on Receptor Tyrosine Kinase (RTK): Implication for Molecular Targeting in Nasopharyngeal Carcinoma (NPC) | Ph.D., Assistant Professor LUI Wai Yan Vivian |
| 2008.365 | Validation Study of Assessment of Capacity for Everday Decision-Making for Chinese Elderly | Dr Lui Wing Cheong |
| 2014.016 | Surgical Outcome of Medial Rectus Resection for Recurrent Exotropia | Dr. LUK Abbie |
| 2015.487 | Retinopathy of Prematurity: Applicability and Compliance of Screening Guidelines in Hong Kong | Dr. LUK Abbie Sheung Wan |
| 2014.441 | A MULTICENTRE RANDOMIZED PROGRAM BY USING A DIABETIC KIDNEY DISEASE (DKD) REGISTRY TO TREAT TO MULTIPLE TARGETS (TMT) (DKD-TMT) | Dr. LUK Andrea |
| 2014.426 | A STUDY TO EVALUATE THE EFFECT OF BTI320 (SUGARDOWN®) ON POST-PRANDIAL HYPERGLYCAEMIA IN HIGH RISK CHINESE SUBJECTS WITH PRE-DIABETES | Dr. LUK Andrea On Yan |
| 2017.298 | Incidence of diabetes and diabetes-related complications in Hong Kong | Dr. LUK Andrea On Yan |
| 2017.436 | Single - Dose, Randomized, Open-Label, Two-Way Crossover Study to Evaluate the Bioequivalence of Azilsartan Tablets in Chinese Healthy Volunteers |
Dr. LUK Andrea On Yan 陸安欣 |
| 2016.046 | Interactive effects of testosterone, estradiol and CAG repeat polymorphism of androgen receptor gene on cardiovascular-renal diseases and mortality in men with type 2 diabetes |
Dr. LUK Andrea On Yan 陸安欣 |
| 2014.056 | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, 26-WEEK MULTICENTER STUDY WITH A 78-WEEK EXTENSION TO EVALUATE THE EFFICACY AND SAFETY OF ERTUGLIFLOZIN IN SUBJECTS WITH TYPE 2 DIABETES MELLITUS AND INADEQUATE GLYCEMIC CONTROL ON METFORMIN MONOTHERAPY | Dr. LUK Andrea On Yan |
| 2017.167 | Single-center, randomized, double-blind, placebo-controlled, single-dose and multiple-dose, parallel-group study to investigate pharmacokinetics, pharmacodynamics, safety and tolerability of vericiguat in Chinese healthy male subjects under fed condition |
Dr. LUK Andrea On Yan 陸安欣 |
| 2017.248 | A different level of single-dose and multiple-dose study to evaluate the pharmacokinetics of ranolazine in a Chinese population |
Dr. LUK Andrea On Yan 陸安欣 |
| 2017.451 | A RANDOMIZED, SPONSOR-OPEN, INVESTIGATOR-BLINDED, SUBJECT-BLINDED, PLACEBO-CONTROLLED, SINGLE AND MULTIPLE ASCENDING DOSE STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND PHARMACODYNAMICS OF RO7020531 AND METABOLITES FOLLOWING ORAL ADMINISTRATION TO CHINESE HEALTHY VOLUNTEERS |
Dr. LUK Andrea On Yan 陸安欣 |
| 2015.208 | Using C-peptide, anti-glutamic acid decarboxylase antibodies and body mass index to identify patients with young-onset type 2 diabetes for early insulin therapy | Dr. LUK Andrea On Yan |
| 2014.699 | Dose-response study of gevokizumab (S 78989 3mg, 10mg, 30mg or 60mg in patients with type 2 diabetes and diabetic kidney disease (DKD). A 66-week, international, multicenter, randomized, double-blind, parallel-group, placebo controlled, study. | Dr. LUK Andrea On Yan |
| 2016.264 | Single center, randomized, open labeled pharmacokinetics study of Azilsartan Tablets in Chinese healthy volunteers | Dr. LUK Andrea On Yan |
| 2015.540 | A randomized, double-blind, placebo-controlled, parallel-group, multicenter, event-driven Phase III study to investigate the efficacy and safety of finerenone, in addition to standard of care, on the progression of kidney disease in subjects with type 2 diabetes mellitus and the clinical diagnosis of diabetic kidney disease |
Prof. LUK Andrea On Yan 陸安欣 |
| 2016.261 | Establishment of a registry on young-onset diabetes in Asia |
Dr. LUK Andrea On Yan 陸安欣 |
| 2016.263 | Pharmacokinetics study of Trazodone Hydrochloride Prolonged-release tablets in Chinese Healthy Volunteers | Dr. LUK Andrea On Yan |
| 2016.297 | A Single-dose Pharmacokinetic/Pharmacodynamic, Safety and Tolerability Study of Subcutaneous Evolocumab Supplied by AML-14 Manufacture Site in Healthy Subjects of Chinese Descent |
Dr. LUK Andrea On Yan 陸安欣 |
| 2017.271 | A RANDOMIZED, SPONSOR-OPEN, INVESTIGATOR–BLIND, SUBJECT-BLIND, PLACEBO-CONTROLLED, SINGLE ASCENDING DOSE, TO INVESTIGATE THE SAFETY, TOLERABILITY AND PHARMACOKINETICS OF RO7062931 FOLLOWING SUBCUTANEOUSLY ADMINISTRATION IN HEALTHY CHINESE VOLUNTEERS |
Dr. LUK Andrea On Yan 陸安欣 |
| 2016.733 | Impact of heavy metal exposure during adolescence on glycemic status and cardio-metabolic risk factors in adulthood |
Dr. LUK Andrea On Yan 陸安欣 |
| 2015.634 | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, 26-WEEK MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ERTUGLIFLOZIN IN ASIAN SUBJECTS WITH TYPE 2 DIABETES MELLITUS AND INADEQUATE GLYCEMIC CONTROL ON METFORMIN MONOTHERAPY |
Dr. LUK Andrea On Yan 陸安欣 |
| 2011.418 | A Multicenter, Controlled, Open-label Extension (OLE) Study to Assess the Long-term Safety and Efficacy of Evolocumab (AMG 145) | Dr. LUK Andrea On Yan |
| 2011.182 | A Randomized, Placebo Controlled Clinical Trial to Evaluate Cardiovascular Outcomes After Treatment with Exenatide Once Weekly in Patients with Type 2 Diabetes Mellitus | Dr. LUK Andrea On Yan |
| 2013.071 | A Multicenter, Open-label Study to Assess the Long-term Safety, Tolerability, and Efficacy of AMG 145 on LDL-C in Subjects With Severe Familial Hypercholesterolemia | Dr. LUK Andrea On Yan |
| 2013.588 | RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO ASSESS CARDIOVASCULAR OUTCOMES FOLLOWING TREATMENT WITH ERTUGLIFLOZIN (MK-8835/PF-04971729) IN SUBJECTS WITH TYPE 2 DIABETES MELLITUS AND ESTABLISHED VASCULAR DISEASE, THE VERTIS CV STUDY | Dr. LUK Andrea On Yan |
| 2011.084 | A randomized controlled study to evaluate the effect of n-3 polyunsaturated fatty acids on the progression of diabetic kidney disease | Dr. Luk Andrea On Yan |
| 2013.070 | A Multicenter, Controlled, Open-label Extension (OLE) Study to Assess the Long-term Safety and Efficacy of AMG 145 | Dr. LUK Andrea On Yan |
| 2012.489 | A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess Cardiovascular Outcomes Following Treatment with MK-3102 in Subjects with Type 2 Diabetes Mellitus | Dr. LUK Andrea On Yan |
| 2020.132 | A Trial Investigating the Pharmacokinetic Properties of Fast-acting Insulin Aspart in Chinese Subjects with Type 1 Diabetes or Type 2 Diabetes |
Dr. LUK Andrea On Yan 陸安欣 |
| 2018.093 | A different level of single-dose and multiple-dose study to evaluate the pharmacokinetics of Bilastine in a Chinese population |
Dr. LUK Andrea On Yan 陸安欣 |
| 2020.032 | Health and Economic Impacts of Pre-Diabetes, Gestational Diabetes, Type 1 and Type 2 Diabetes in Hong Kong |
Dr. LUK Andrea On Yan 陸安欣 |
| 2020.438 | Delineating the metabolic architecture and response to anti-hyperglycaemic drug treatment in lean type 2 diabetes in Chinese | Dr. LUK Andrea On Yan |
Page 174 of 289.